Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Marc Humbert (Le Kremlin-Bicêtre, France), Marc Humbert, Hossein-Ardeschir Ghofrani, Dennis Busse, Janethe de Olivereira Pena, David Langleben. Riociguat in pulmonary arterial hypertension: ERS/ESC risk assessment in PATENT. Eur Respir J 2016; 48: Suppl. 60, 2401

Member's Comments

No comment yet.

Related content which might interest you: Riociguat in chronic thromboembolic pulmonary hypertension (CTEPH): ERS/ESC risk assessment in CHEST Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension Year: 2016 Riociguat for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Real-life data from the EXPERT registry Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Riociguat for the treatment of pulmonary hypertension: Safety data from the EXPERT registry Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Pulmonary hypertension correction in patients with chronic obstructive pulmonary disease and essential hypertension Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Specific pulmonary arterial hypertension therapy in COPD patients with severe pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Effect of pulmonary-specific vasodilator therapy in patients with chronic obstructive pulmonary disease and pulmonary hypertension. A retrospective analysis Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 LATE-BREAKING ABSTRACT: Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 2-year results from the CHEST-2 long-term extension Source: International Congress 2014 – New technologies and biomarkers in lung disease Year: 2014 Acute haemodynamic effects of adaptive servoventilation therapy in patients with pulmonary arterial hypertension and patients with chronic thromboembolic pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 HbA1c-levels in patients with operable chronic thromboembolic pulmonary hypertension Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 RESPITE: Riociguat in pulmonary arterial hypertension patients with an inadequate response to phosphodiesterase type 5 inhibitors Source: International Congress 2016 – Clinic of pulmonary hypertension Year: 2016 Effects of riociguat in patients with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following pulmonary endarterectomy (PEA) Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Pulmonary vascular reactivity in pulmonary hypertension due to left heart disease Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology Source: Eur Respir Rev 2009; 19: 59-63 Year: 2010 Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: Eur Respir J, 53 (6) 1802004; 10.1183/13993003.02004-2018 Year: 2019 Cardiopulmonary comorbidities are associated with hemodynamics in pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Risk factors of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Global fibrinolytic profile in patients with chronic thromboembolic pulmonary hypertension Source: International Congress 2015 – Pulmonary circulation: pulmonary embolism and chronic thromboembolic pulmonary hypertension Year: 2015 Unique characteristics of patients with pulmonary arterial hypertension associated with congenital heart disease compared to the rest of pulmonary arterial hypertension subgroups Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Adherence to pulmonary arterial hypertension targeted therapies Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015